Jaguar Animal Health (NASDAQ:JAGX) Shares Cross Above Fifty Day Moving Average – Should You Sell?

Jaguar Animal Health, Inc. (NASDAQ:JAGX)’s stock price passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $12.76 and traded as high as $41.53. Jaguar Animal Health shares last traded at $34.46, with a volume of 27,094,223 shares changing hands.

Jaguar Animal Health News Roundup

Here are the key news stories impacting Jaguar Animal Health this week:

• Positive Sentiment: Jaguar’s shares recently moved above their 50-day moving average, a technical development that could attract momentum traders, although the signal has been overshadowed by subsequent volatility. Jaguar Animal Health Stock Passes Above 50-Day Moving Average
• Neutral Sentiment: Trading in JAGX was repeatedly halted under Nasdaq’s Limit Up-Limit Down mechanism on September 23, highlighting unusually sharp price movements and elevated execution risk for investors.
• Neutral Sentiment: A September 24 short-interest update reported zero shares sold short and a zero-day days-to-cover ratio based on average volume. That suggests short covering is not currently a material catalyst, though the reported figures appear inconsistent with the description of a large increase in short interest.
• Negative Sentiment: The primary current overhang is a debt-for-equity exchange, which raises concerns about additional shares entering the market and dilution for existing shareholders. Those concerns are weighing on the micro-cap biotechnology stock. Jaguar Health Stock Slides Thursday: What’s Happening?
• Negative Sentiment: The stock’s sharp prior rally, fueled by regulatory fee waivers, prompted profit-taking and a reversal as traders locked in gains. The move appears company-specific rather than part of a broad biotechnology selloff. Jaguar Health Stock Plunges Wednesday: What’s Happening?
• Negative Sentiment: Reports also grouped JAGX among biotech stocks moving sharply lower after company-specific financing news, reinforcing that offering and dilution concerns—not sector-wide weakness—are driving sentiment. Viking Therapeutics Sinks After Offering; Jaguar Health Tumbles

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Jaguar Animal Health presently has a consensus rating of “Sell”.

Jaguar Animal Health Price Performance

The firm’s fifty day moving average is $12.36 and its two-hundred day moving average is $80.30. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.69 and a quick ratio of 0.40.

Jaguar Animal Health (NASDAQ:JAGX) last released its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) EPS for the quarter, topping analysts’ consensus estimates of ($782.25) by $766.55. The company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $4.24 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on developing and commercializing medicines and health products for animals. The company’s research is centered on naturally derived compounds, particularly plant-based products designed to address gastrointestinal disorders and other health conditions in companion and production animals.

Jaguar’s portfolio and development programs include products for dogs, cats, horses and livestock. Its best-known product is Canalevia-CA1, a crofelemer-based prescription product that received conditional approval from the U.S.